|
||
|
Total reimbursement value for antiosteoporotic drugs, granted under the NIHF in the RBG (2015–2018). |
|
||||||||
| Part of: Chakuleska L, Simeonova R, Danchev N (2020) Pharmacotherapy costs and medicines reimbursement policies of osteoporosis in the Republic of Bulgaria and Republic of North Macedonia. Pharmacia 67(4): 199-207. https://doi.org/10.3897/pharmacia.67.e55835 |